Dramatic response to cabozantinib in patients with hyperprogression after anti-PD-1 therapy

被引：0
|
作者：
Schlack, K. [1 ]
Krabbe, L. -M [1 ]
Schrader, A. J. [1 ]
Klaile, Y. [1 ]
Boegemann, M. [1 ]
机构：
[1] Univ Klinikum Munster, Klin Urol & Kinderurol, Munster, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P607
引用
收藏
页码：203 / 204
页数：2
相关论文
共 50 条
  • [1] Hyperprogression of cutaneous T cell lymphoma after anti-PD-1 treatment
    Gao, Y.
    Wang, Y.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S48 - S48
  • [2] Hyperprogression of cutaneous T cell lymphoma after anti-PD-1 treatment
    Gao, Yumei
    Hu, Simeng
    Li, Ruoyan
    Jin, Shanzhao
    Liu, Fengjie
    Liu, Xiangjun
    Li, Yingyi
    Yan, Yicen
    Liu, Weiping
    Gong, Jifang
    Yang, Shuxia
    Tu, Ping
    Shen, Lin
    Bai, Fan
    Wang, Yang
    JCI INSIGHT, 2023, 8 (04)
  • [3] Dramatic Response to Concurrent Anti-PD-1 Therapy and Radiation in Resistant Tumors with Sarcomatoid Differentiation
    Tolay, Sameer
    Nair, Ranjit
    McIntosh, Alyson F.
    Sopka, Dennis M.
    Nair, Suresh G.
    ONCOLOGIST, 2019, 24 (01): : E49 - E52
  • [4] Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
    Saada-Bouzid, E.
    Defaucheux, C.
    Karabajakian, A.
    Coloma, V. P.
    Servois, V.
    Paoletti, X.
    Even, C.
    Fayette, J.
    Guigay, J.
    Loirat, D.
    Peyrade, F.
    Alt, M.
    Gal, J.
    Le Tourneau, C.
    ANNALS OF ONCOLOGY, 2017, 28 (07) : 1605 - 1611
  • [5] Cabozantinib in patients with locally advanced or metastatic urothelial cell carcinoma who have progressed after cisplatin-based chemotherapy and anti-PD-1/PD-L1 therapy or after anti-PD-1/PD-L1 therapy only.
    Bartsch, Georg
    Thomas, Christian
    Tsaur, Igor
    Schnabel, Marco
    Haferkamp, Axel
    Gorbulev, Stanislav
    Ruckes, Christian
    Kronfeld, Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [6] Molecular features of response to anti-PD-1 therapy
    Schadendorf, Dirk
    Schilling, Bastian
    CHINESE CLINICAL ONCOLOGY, 2016, 5 (06)
  • [7] Hyperprogression on anti-PD-1 treatment. Is subsequent therapy feasible? A case report and review of the literature
    Skacel, Jan
    Melichar, Bohuslav
    Mohelnikova-Duchonova, Beatrice
    Lemstrova, Radmila
    BIOMEDICAL PAPERS-OLOMOUC, 2023, 167 (04): : 376 - 384
  • [8] Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases
    Yang, Yan
    Ding, Liren
    Wang, Pingli
    JOURNAL OF THORACIC DISEASE, 2016, 8 (07) : E535 - E537
  • [9] Predominance of hyperprogression in mucosal melanoma during anti-PD-1 monotherapy treatment
    Zhou, Li
    Cao, Min
    Zhu, Haibin
    Chi, Zhihong
    Cui, Chuanliang
    Sheng, Xinan
    Mao, Lili
    Lian, Bin
    Tang, Bixia
    Yan, Xieqiao
    Bai, Xue
    Wang, Xuan
    Li, Siming
    Guo, Jun
    Sun, Ying-shi
    Si, Lu
    ONCOLOGIST, 2024,
  • [10] Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
    Afzal, Muhammad Zubair
    Mabaera, Rodwell
    Shirai, Keisuke
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
12345